Developer docs
API playgroundTry for free, no card

Search company profiles

Openwater

Full company profile

uuid00003uc

Namestring
Openwater
Legal namestring
Open Water Internet, Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Openwater (legal entity Open Water Internet, Inc.) is a San Francisco-based, privately held medical technology company founded around 2015 that develops wearable devices for non-invasive brain imaging and stimulation. Its two core platforms are Open-Motion, a wearable cerebral blood flow imaging system using laser-based diffuse correlation spectroscopy with FPGA-processed histogram data from multi-camera sensor modules, and Open-LIFU, a wearable headset delivering low-intensity focused ultrasound neuromodulation via 64-element 2D matrix arrays at 155 kHz or 400 kHz. Both products are investigational and labeled for research use only, and the company has published clinical results across LVO stroke diagnosis, treatment-resistant depression, glioblastoma oncology, and long COVID symptoms. The platform is built on open-source principles: hardware under CC BY-SA 4.0 and software under AGPL, with a public Patent Pledge, a GitHub ecosystem, Python SDKs (openlifu-python, openmotion-sdk), and integrations including 3D Slicer, EEG amplifiers, analog DAQ, and TMS/tACS stimulators. Openwater sells hardware via Order Forms to research institutions and clinical researchers (named deployments include MIT and Hospital del Mar Research Institute in Barcelona), offers annual Cloud Services subscriptions for photogrammetry processing, and provides fee-based Orientation and Training, Virtual Technical Support, Clinical-Technical Case-Day Support, and an optional Annual Platform Support and Maintenance (APSM) program. Investors include Bold Capital Partners, Khosla Ventures (Series 2 lead), Collaborative Fund, Plum Alley, Excel Venture Management, KittyHawk, and Starlight Ventures, with cumulative disclosed funding of approximately $76M including a $54M round in August 2024.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable ultrasound devices, focused ultrasound neuromodulation, cerebral blood flow imaging, open-source medical technology, low-intensity focused ultrasound
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Therapeutic Ultrasound Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Hardware Product Sales
TypeHardware Sales
Description

Openwater sells Open-LIFU and Open-Motion hardware platforms (Console, Transducer/Sensor Modules, accessories) to research institutions and clinical researchers. Products are sold under research-use-only terms with a one-year limited warranty. Fees are set in Order Forms; the company ships FOB from its manufacturing facility.

openwater.health
2Cloud Services Subscription
TypeSubscription Recurring
Description

Subscription-based cloud-hosted software and processing capabilities (photogrammetry reconstruction, spatial registration workflows) available on an annual subscription basis per named or concurrent users and processing unit quotas. Provided alongside the Openwater Photogrammetry app.

openwater.health
3Professional Services
TypeProfessional Services
Description

Orientation & Training (on-site or remote), Virtual Technical Support, Annual Platform Support and Maintenance (APSM), Clinical-Technical Case-Day Support, and custom Professional Services (engineering, consulting, data analysis, study design). Billed on time-and-materials or fixed-price basis per Order Form.

openwater.health
4Annual Platform Support and Maintenance (APSM)
TypeManaged Services
Description

Optional renewable annual support and maintenance program for eligible Products providing technical support, software updates, bug fixes, and repair/replacement coverage. Begins post-warranty and renews automatically unless cancelled.

openwater.health
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales
Pricing details3 tiers
1Research institution / enterprise hardware purchase — no public pricing
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Hardware is sold via Order Forms with pricing quoted upon request. Title and risk of loss pass to Customer upon delivery to the shipping carrier. Customer is responsible for obtaining insurance against damage during shipping.

openwater.health
2Cloud Services subscription — annual subscription model
ModelSubscriptionBilling cadenceAnnual
Notes

Cloud Services are licensed on an annual subscription basis per named or concurrent users and included processing units per subscription period. Overage fees may apply. Auto-renews annually unless cancelled with 30 days' notice.

openwater.health
3Annual Platform Support and Maintenance (APSM)
ModelSubscriptionBilling cadenceAnnual
Notes

Optional post-warranty annual support and maintenance program renewable each year at then-current fees.

openwater.health
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Open-Motion
Description

Wearable infrared light device for cerebral blood flow imaging and stroke diagnosis.

openwater.health
+1 more record
Core offering1 text field

Openwater develops wearable, open-source medical hardware platforms built on semiconductor manufacturing: Open-LIFU is a Low-Intensity Focused Ultrasound (LIFU) headset for non-invasive neuromodulation, and Open-Motion is a wearable optical cerebral blood flow imaging system using near-infrared diffuse correlation spectroscopy. Both platforms are sold as research-use-only devices to universities, hospitals, and clinical researchers via direct Order Forms, supported by AGPL/CC BY-SA 4.0 open-source hardware and software, Python SDKs, an annual Cloud Services subscription for photogrammetry, and optional Annual Platform Support and Maintenance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Response rates of up to 60% and remission in 35% of participants after three weeks of focused ultrasound neuromodulation treatment (University of Arizona research)
+2 more records
Product overview1 text field

Openwater offers an open-source medical technology platform centered on two core therapeutic devices: Open-Motion (cerebral blood flow imaging using laser-based diffuse correlation spectroscopy with wearable sensor modules) and Open-LIFU (low-intensity focused ultrasound neuromodulation with wearable headset transducers). Both devices share supporting software infrastructure including cloud services for photogrammetry processing, desktop applications for device control and planning, Python SDKs/APIs for programmatic access, and Slicer extensions for advanced research integration. The platform is built on open-source principles with AGPL-licensed software and CC BY-SA 4.0 hardware designs. All products are investigational devices labeled for research use only.

Product and service3 records
1Open-LIFU
CategoryTherapeutic Ultrasound Devices
Description

Low-Intensity Focused Ultrasound (LIFU) neuromodulation platform with wearable headset transducer containing one or two 64-element 2D matrix array transmit modules operating at 155 kHz or 400 kHz, paired with a Console (high-voltage power supplies, timing controllers) and a deformable hydrogel coupling pad. Supports programmable sonication sequences (focal pressure, pulse duration, pulse train parameters) and uses Android-based photogrammetry for spatial registration of the transducer to subject anatomy. Designed for research institutions and clinical researchers studying depression, stroke, glioblastoma, long COVID, autoimmune conditions, and BCI applications.

2Open-Motion
CategoryMedical Imaging Devices
Description

Wearable optical cerebral blood flow imaging system based on near-infrared diffuse correlation spectroscopy (DCS). Each Sensor Module houses eight camera sensors (1920×1280 at 40 Hz) with on-module Lattice Crosslink FPGA processing generating 1024-bin histograms; the Console houses a 795 nm Class 1 laser (12 mW average power, 250–1000 μs pulse duration, 40 Hz repetition rate) with a fiber splitter and provides blood flow and volume metrics through a Python SDK. Designed for research institutions and clinical researchers studying stroke diagnosis, neurological monitoring, and multimodal physiological recording aligned with EEG, TMS/tACS, and analog DAQ systems.

3Openwater Cloud Services
CategoryCloud Software Services
Description

Subscription-based cloud-hosted software and processing capabilities for photogrammetry reconstruction and 3D mesh generation, interoperating with the Openwater Photogrammetry app and Open-LIFU system for spatial registration workflows. Licensed on an annual subscription basis per named or concurrent users with included processing unit quotas and potential overage fees; auto-renews annually unless cancelled with 30 days' notice.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1TIESA (Austria)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

TIESA, an Austrian-based mental health research company, is using Openwater's Open-LIFU platform for AI-driven, noninvasive neuromodulation research targeting depression, anxiety, and other mental health conditions. The research aims to modulate the brain's Default Mode Network (DMN) using closed-loop focused ultrasound stimulation. Patient enrollment is expected to begin in early 2026. This partnership represents Openwater's integration of focused ultrasound into real-world research-driven care programs. The approach is supported by University of Arizona research showing response rates of up to 60% and remission in 35% of participants after three weeks of treatment.

lenconnect.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Kernel develops wearable, non-invasive brain measurement and stimulation devices using optical and electromagnetic methods. Conceptually adjacent to Openwater's vision of semiconductor-manufactured, wearable brain-interfacing hardware.

TypeDirect peer
Description

InSightec develops FDA-cleared focused-ultrasound systems (e.g., Exablate Neuro) for incisionless neurosurgery including tremor, Parkinson's, and essential tremor — the most established direct competitor to Openwater's LIFU platform, working on the same therapeutic modality for the same indication categories.

3HistoSonics
TypeDirect peer
Description

HistoSonics commercializes histotripsy focused-ultrasound platforms for non-invasive tissue ablation. Same core technology (therapeutic focused ultrasound) targeting multiple disease areas via a platform approach analogous to Open-LIFU.

TypeEmerging player
Description

Cordance Medical is developing focused-ultrasound platforms for blood-brain barrier opening and targeted drug delivery in brain disorders — closely aligned application area with Open-LIFU's neuromodulation focus and similar early-stage clinical positioning.

TypeEmerging player
Description

NaviFUS develops non-invasive focused-ultrasound systems for neurological indications including brain tumors and neurodegenerative diseases. Direct therapeutic-modality overlap with Openwater's LIFU approach.

TypeDirect peer
Description

BrainsWay markets FDA-cleared Deep Transcranial Magnetic Stimulation systems for depression, OCD, and other mental health conditions — a competing non-invasive neuromodulation modality targeting the same treatment-resistant depression use case Open-LIFU addresses.

TypeBroad incumbent
Description

NeuroPace's RNS System is an FDA-approved closed-loop brain stimulation device for epilepsy. Comparable closed-loop neurostimulation philosophy and direct overlap with Openwater's AI-driven closed-loop stimulation road map.

TypeDirect peer
Description

Soterix Medical manufactures non-invasive neuromodulation and neurodiagnostic devices including tDCS, tACS, and HD-tDCS platforms for research and clinical use — comparable technology category and customer base (research institutions and clinical researchers).

TypeEmerging player
Description

Hyperfine has commercialized the FDA-cleared portable Swoop MRI system — an adjacent paradigm of making hospital-grade brain imaging accessible in non-traditional settings, mirroring Openwater's goals of displacing expensive infrastructure-dependent medical equipment.

TypeEmerging player
Description

eNeura markets a non-invasive transcranial magnetic stimulation device (SpringTMS) for migraine treatment — a relevant non-invasive brain stimulation peer with FDA clearance in a neurological indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Openwater

Therapeutic Ultrasound Devicesopenwater.health

What Openwater does

Openwater (legal entity Open Water Internet, Inc.) is a San Francisco-based, privately held medical technology company founded around 2015 that develops wearable devices for non-invasive brain imaging and stimulation. Its two core platforms are Open-Motion, a wearable cerebral blood flow imaging system using laser-based diffuse correlation spectroscopy with FPGA-processed histogram data from multi-camera sensor modules, and Open-LIFU, a wearable headset delivering low-intensity focused ultrasound neuromodulation via 64-element 2D matrix arrays at 155 kHz or 400 kHz. Both products are investigational and labeled for research use only, and the company has published clinical results across LVO stroke diagnosis, treatment-resistant depression, glioblastoma oncology, and long COVID symptoms. The platform is built on open-source principles: hardware under CC BY-SA 4.0 and software under AGPL, with a public Patent Pledge, a GitHub ecosystem, Python SDKs (openlifu-python, openmotion-sdk), and integrations including 3D Slicer, EEG amplifiers, analog DAQ, and TMS/tACS stimulators. Openwater sells hardware via Order Forms to research institutions and clinical researchers (named deployments include MIT and Hospital del Mar Research Institute in Barcelona), offers annual Cloud Services subscriptions for photogrammetry processing, and provides fee-based Orientation and Training, Virtual Technical Support, Clinical-Technical Case-Day Support, and an optional Annual Platform Support and Maintenance (APSM) program. Investors include Bold Capital Partners, Khosla Ventures (Series 2 lead), Collaborative Fund, Plum Alley, Excel Venture Management, KittyHawk, and Starlight Ventures, with cumulative disclosed funding of approximately $76M including a $54M round in August 2024.

Openwater firmographics

Firmographics
Name
Openwater
Legal name
Open Water Internet, Inc.
Website
https://openwater.health
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where Openwater is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Openwater business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Hardware Product Sales: Openwater sells Open-LIFU and Open-Motion hardware platforms (Console, Transducer/Sensor Modules, accessories) to research institutions and clinical researchers. Products are sold under research-use-only terms with a one-year limited warranty. Fees are set in Order Forms; the company ships FOB from its manufacturing facility.
  2. Cloud Services Subscription: Subscription-based cloud-hosted software and processing capabilities (photogrammetry reconstruction, spatial registration workflows) available on an annual subscription basis per named or concurrent users and processing unit quotas. Provided alongside the Openwater Photogrammetry app.
  3. Professional Services: Orientation & Training (on-site or remote), Virtual Technical Support, Annual Platform Support and Maintenance (APSM), Clinical-Technical Case-Day Support, and custom Professional Services (engineering, consulting, data analysis, study design). Billed on time-and-materials or fixed-price basis per Order Form.
  4. Annual Platform Support and Maintenance (APSM): Optional renewable annual support and maintenance program for eligible Products providing technical support, software updates, bug fixes, and repair/replacement coverage. Begins post-warranty and renews automatically unless cancelled.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractResearch institution / enterprise hardware purchase — no public pricing
SubscriptionAnnualCloud Services subscription — annual subscription model
SubscriptionAnnualAnnual Platform Support and Maintenance (APSM)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Openwater product offering

Product offering

Core offering

Openwater develops wearable, open-source medical hardware platforms built on semiconductor manufacturing: Open-LIFU is a Low-Intensity Focused Ultrasound (LIFU) headset for non-invasive neuromodulation, and Open-Motion is a wearable optical cerebral blood flow imaging system using near-infrared diffuse correlation spectroscopy. Both platforms are sold as research-use-only devices to universities, hospitals, and clinical researchers via direct Order Forms, supported by AGPL/CC BY-SA 4.0 open-source hardware and software, Python SDKs, an annual Cloud Services subscription for photogrammetry, and optional Annual Platform Support and Maintenance.

Product overview

Openwater offers an open-source medical technology platform centered on two core therapeutic devices: Open-Motion (cerebral blood flow imaging using laser-based diffuse correlation spectroscopy with wearable sensor modules) and Open-LIFU (low-intensity focused ultrasound neuromodulation with wearable headset transducers). Both devices share supporting software infrastructure including cloud services for photogrammetry processing, desktop applications for device control and planning, Python SDKs/APIs for programmatic access, and Slicer extensions for advanced research integration. The platform is built on open-source principles with AGPL-licensed software and CC BY-SA 4.0 hardware designs. All products are investigational devices labeled for research use only.

Differentiator

Problem solved

Functional benefit

Brands

  • Open-Motion: Wearable infrared light device for cerebral blood flow imaging and stroke diagnosis.
  • Open-LIFU

Products and services

  • Open-LIFU Low-Intensity Focused Ultrasound (LIFU) neuromodulation platform with wearable headset transducer containing one or two 64-element 2D matrix array transmit modules operating at 155 kHz or 400 kHz, paired with a Console (high-voltage power supplies, timing controllers) and a deformable hydrogel coupling pad. Supports programmable sonication sequences (focal pressure, pulse duration, pulse train parameters) and uses Android-based photogrammetry for spatial registration of the transducer to subject anatomy. Designed for research institutions and clinical researchers studying depression, stroke, glioblastoma, long COVID, autoimmune conditions, and BCI applications.
  • Open-Motion Wearable optical cerebral blood flow imaging system based on near-infrared diffuse correlation spectroscopy (DCS). Each Sensor Module houses eight camera sensors (1920×1280 at 40 Hz) with on-module Lattice Crosslink FPGA processing generating 1024-bin histograms; the Console houses a 795 nm Class 1 laser (12 mW average power, 250–1000 μs pulse duration, 40 Hz repetition rate) with a fiber splitter and provides blood flow and volume metrics through a Python SDK. Designed for research institutions and clinical researchers studying stroke diagnosis, neurological monitoring, and multimodal physiological recording aligned with EEG, TMS/tACS, and analog DAQ systems.
  • Openwater Cloud Services Subscription-based cloud-hosted software and processing capabilities for photogrammetry reconstruction and 3D mesh generation, interoperating with the Openwater Photogrammetry app and Open-LIFU system for spatial registration workflows. Licensed on an annual subscription basis per named or concurrent users with included processing unit quotas and potential overage fees; auto-renews annually unless cancelled with 30 days' notice.

Quantifiable outcome

  • Response rates of up to 60% and remission in 35% of participants after three weeks of focused ultrasound neuromodulation treatment (University of Arizona research)
  • +2 more outcomes

Companies that use Openwater

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Openwater technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability7 records

Feature5 records

Openwater partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • TIESA (Austria)coreStrategic or Co-development Partner · 1 January 2026TIESA, an Austrian-based mental health research company, is using Openwater's Open-LIFU platform for AI-driven, noninvasive neuromodulation research targeting depression, anxiety, and other mental health conditions. The research aims to modulate the brain's Default Mode Network (DMN) using closed-loop focused ultrasound stimulation. Patient enrollment is expected to begin in early 2026. This partnership represents Openwater's integration of focused ultrasound into real-world research-driven care programs. The approach is supported by University of Arizona research showing response rates of up to 60% and remission in 35% of participants after three weeks of treatment.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Openwater competitors and assessment

Company assessment

Emerging players

  • Kernel: Kernel develops wearable, non-invasive brain measurement and stimulation devices using optical and electromagnetic methods. Conceptually adjacent to Openwater's vision of semiconductor-manufactured, wearable brain-interfacing hardware.
  • Cordance Medical: Cordance Medical is developing focused-ultrasound platforms for blood-brain barrier opening and targeted drug delivery in brain disorders — closely aligned application area with Open-LIFU's neuromodulation focus and similar early-stage clinical positioning.
  • NaviFUS: NaviFUS develops non-invasive focused-ultrasound systems for neurological indications including brain tumors and neurodegenerative diseases. Direct therapeutic-modality overlap with Openwater's LIFU approach.
  • Hyperfine: Hyperfine has commercialized the FDA-cleared portable Swoop MRI system — an adjacent paradigm of making hospital-grade brain imaging accessible in non-traditional settings, mirroring Openwater's goals of displacing expensive infrastructure-dependent medical equipment.
  • eNeura: eNeura markets a non-invasive transcranial magnetic stimulation device (SpringTMS) for migraine treatment — a relevant non-invasive brain stimulation peer with FDA clearance in a neurological indication.

Direct peers

  • InSightec: InSightec develops FDA-cleared focused-ultrasound systems (e.g., Exablate Neuro) for incisionless neurosurgery including tremor, Parkinson's, and essential tremor — the most established direct competitor to Openwater's LIFU platform, working on the same therapeutic modality for the same indication categories.
  • HistoSonics: HistoSonics commercializes histotripsy focused-ultrasound platforms for non-invasive tissue ablation. Same core technology (therapeutic focused ultrasound) targeting multiple disease areas via a platform approach analogous to Open-LIFU.
  • BrainsWay: BrainsWay markets FDA-cleared Deep Transcranial Magnetic Stimulation systems for depression, OCD, and other mental health conditions — a competing non-invasive neuromodulation modality targeting the same treatment-resistant depression use case Open-LIFU addresses.
  • Soterix Medical: Soterix Medical manufactures non-invasive neuromodulation and neurodiagnostic devices including tDCS, tACS, and HD-tDCS platforms for research and clinical use — comparable technology category and customer base (research institutions and clinical researchers).

Broad incumbents

  • NeuroPace: NeuroPace's RNS System is an FDA-approved closed-loop brain stimulation device for epilepsy. Comparable closed-loop neurostimulation philosophy and direct overlap with Openwater's AI-driven closed-loop stimulation road map.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Openwater social profiles

Digital presence

Openwater compliance and trust

Trust signal

Compliance2 records

Openwater financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Openwater leadership team

Management profile

Number of profiles

Profiles4 records

Openwater funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Openwater M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Openwater

What does Openwater do?

Openwater develops wearable, open-source medical hardware platforms built on semiconductor manufacturing: Open-LIFU is a Low-Intensity Focused Ultrasound (LIFU) headset for non-invasive neuromodulation, and Open-Motion is a wearable optical cerebral blood flow imaging system using near-infrared diffuse correlation spectroscopy. Both platforms are sold as research-use-only devices to universities, hospitals, and clinical researchers via direct Order Forms, supported by AGPL/CC BY-SA 4.0 open-source hardware and software, Python SDKs, an annual Cloud Services subscription for photogrammetry, and optional Annual Platform Support and Maintenance.

Is Openwater a public or private company?

Openwater is a private company. It is classified as venture growth investor backed and is currently operating.

When was Openwater founded?

Openwater was founded in 2015. It employs 11 to 50 people.

Where is Openwater based?

Openwater is headquartered in San Francisco, United States, in the North America region.

How does Openwater make money?

Four revenue lines are on record. Hardware Product Sales are the primary driver. The others are cloud Services Subscription, professional Services and annual Platform Support and Maintenance (APSM).

Who are Openwater's main competitors?

Emerging players on record are Kernel, Cordance Medical, NaviFUS, Hyperfine and eNeura. Direct peers are InSightec, HistoSonics, BrainsWay and Soterix Medical. NeuroPace is listed as a broad incumbent.

Does Openwater have an API?

Yes. Python SDK (openmotion-sdk) provides programmatic device control, data acquisition, and visualization for Open-Motion systems. The SDK enumerates and connects to aggregators and console, reads and parses 16-camera histogram streams, computes blood flow and volume metrics, and provides real-time visualization and logging. Also available: openlifu-python with object-oriented interfaces for each Open-LIFU system component. Developer documentation is at github.com/OpenwaterHealth/openmotion-sdk.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartuptodaySolvay has completed a 23 billion won Series C investment... accelerating the scale-up of all-solid-state electrolytes.Solivis completed a 23 billion won Series C investment to expand production infrastructure for sulfide-based solid electrolytes. The round raised total accumulated investment to 65.2 billion won, and the company plans to use funds for automated processes and diversifying its material lineup.EIN PresswirePelara Launches Its First U.S. Veterinary Clinical Trials of Low-Intensity Focused UltrasoundPelara launched its first U.S. veterinary clinical trials of Low-Intensity Focused Ultrasound (LIFU) in partnership with Openwater and SecureDX, targeting chronic pain in dogs, cats, and horses. The trials aim to generate species-specific evidence for commercial deployment, addressing a $2B+ global undertreated market.Florida TodayOpenwater’s Open-LIFU Device Supports Concierge Mental Health Research with TIESAOpenwater, a San Francisco-based open-source medical technology company, announced that Austria-based TIESA will use its Open-LIFU platform for focused ultrasound neuromodulation research targeting depression, anxiety, and other mental health conditions. TIESA aims to modulate the Default Mode Network using precise, noninvasive brain stimulation, supported by research showing response rates of up to 60% and remission in 35% of participants after three weeks of treatment, with patient enrollment expected to begin in early 2026. Open-LIFU remains investigational and available for research use only, though it is already in active use at research institutions including MIT and Hospital del Mar Research Institute in Barcelona.Ventura County StarOpenwater’s Open-LIFU Device Supports Concierge Mental Health Research with TIESAOpenwater, an open-source medical technology company, announced that Austria-based TIESA will use its Open-LIFU platform for focused ultrasound neuromodulation research targeting depression, anxiety, and other mental health conditions through modulation of the brain's Default Mode Network. TIESA expects to begin enrolling patients into Open-LIFU-based research programs in early 2026, with the approach supported by University of Arizona research showing response rates of up to 60% and remission in 35% of participants after three weeks of treatment. The Open-LIFU device remains investigational and available for research use only, not cleared as a standalone treatment.Victorville Daily PressOpenwater’s Open-LIFU Device Supports Concierge Mental Health Research with TIESAOpenwater's Open-LIFU device is being used by TIESA for noninvasive neuromodulation research targeting mental health conditions such as depression and anxiety. The research aims to modulate the Default Mode Network in the brain, with patient enrollment expected to begin in early 2026.Palm Beach Daily NewsOpenwater’s Open-LIFU Device Supports Concierge Mental Health Research with TIESAOpenwater announced that TIESA will use its Open-LIFU platform for focused ultrasound neuromodulation research targeting depression, anxiety, and trauma-related mental health conditions. The Austrian-based company plans to begin enrolling patients in early 2026, utilizing AI-driven, closed-loop neurostimulation to modulate the brain's Default Mode Network. The partnership represents an expansion of Open-LIFU into real-world research-driven care programs, with the device remaining investigational and available for research use only.The Daily TelegramOpenwater’s Open-LIFU Device Supports Concierge Mental Health Research with TIESAOpenwater announced that Austrian-based TIESA will use its Open-LIFU focused ultrasound platform to research neuromodulation treatments for depression, anxiety, and other mental health conditions, targeting the brain's Default Mode Network. TIESA expects to begin enrolling patients into Open-LIFU-based research programs in early 2026, utilizing AI-driven closed-loop neurostimulation. The Open-LIFU device remains investigational and available for research use only, with early studies from the University of Arizona showing response rates of up to 60% in participants after three weeks of treatment.The Greenville NewsOpenwater’s Open-LIFU Device Supports Concierge Mental Health Research with TIESAOpenwater announced that Austrian-based TIESA will use its Open-LIFU focused ultrasound platform for research on neuromodulation targeting depression, anxiety, and other mental health conditions, with patient enrollment expected to begin in early 2026. The research aims to modulate the Default Mode Network (DMN) using AI-driven, closed-loop neurostimulation as part of TIESA's non-pharmacologic mental health treatment programs. Openwater's Open-LIFU device, currently available for research use only and already deployed at institutions including MIT, will be integrated into TIESA's personalized, data-driven clinical research process.Panama City News-HeraldOpenwater’s Open-LIFU Device Supports Concierge Mental Health Research with TIESAOpenwater, a San Francisco-based medical technology company, announced that Austrian company TIESA will use its Open-LIFU platform to conduct focused ultrasound neuromodulation research for depression, anxiety, and other mental health conditions. TIESA aims to study and modulate the Default Mode Network using AI-driven, closed-loop neurostimulation, with patient enrollment expected to begin in early 2026. The Open-LIFU device remains investigational and for research use only, not cleared as a standalone treatment.The Florida Times-UnionOpenwater’s Open-LIFU Device Supports Concierge Mental Health Research with TIESAOpenwater announced that Austrian-based company TIESA will use its Open-LIFU focused ultrasound platform for neuromodulation research targeting mental health conditions including depression and anxiety. The research will study modulation of the Default Mode Network and is expected to begin enrolling patients in early 2026, with initial clinical data supported by University of Arizona research showing response rates of up to 60%. The Open-LIFU device remains investigational and available for research use only, not as a cleared standalone treatment.